A Double-Masked, Randomized, Active-Controlled Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]) in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion
Latest Information Update: 29 Nov 2022
At a glance
- Drugs Aflibercept (Primary)
- Indications Branch retinal vein occlusion
- Focus Registrational; Therapeutic Use
- Acronyms VIBRANT
- Sponsors Regeneron Pharmaceuticals
- 28 Nov 2022 Results of post hoc analysis of studies(COPERNICUS and GALILEO trials for CRVO and VIBRANT trial) assessing Correlation between change in central subfield thickness and change in visual acuity in macular edema due to retinal vein occlusion published in the Graefes Archive for Clinical and Experimental Ophthalmology
- 26 Jun 2015 According to a Regeneron Pharmaceuticals media release, Aflibercept received approval in Japan by the MHLW for the treatment of patients with macular edema secondary to retinal vein occlusion based on results of this study.
- 26 Jun 2015 Results published in Santen Pharmaceutical media release.